By otakuyassine3@gmail.com 
Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI – Get Free Report) have received an average rating of “Hold” from the fifteen ratings firms that are currently covering the stock, Marketbeat Ratings reports. Nine analysts have rated the stock with a hold recommendation, five have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price target among analysts that have covered the stock in the last year is $106.08.
A number of equities research analysts have commented on the stock. Cantor Fitzgerald upgraded shares of Intra-Cellular Therapies from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, January 14th. Leerink Partnrs cut shares of Intra-Cellular Therapies from a “strong-buy” rating to a “hold” rating in a research note on Monday, January 13th. Mizuho cut shares of Intra-Cellular Therapies from an “outperform” rating to a “neutral” rating and decreased their target price for the stock from $140.00 to $132.00 in a research note on Monday, February 24th. Canaccord Genuity Group lowered shares of Intra-Cellular Therapies from a “buy” rating to a “hold” rating and increased their price objective for the company from $119.00 to $132.00 in a report on Friday, January 31st. Finally, Baird R W lowered shares of Intra-Cellular Therapies from a “strong-buy” rating to a “hold” rating in a report on Monday, January 13th.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently modified their holdings of ITCI. Wealth Enhancement Advisory Services LLC grew its holdings in shares of Intra-Cellular Therapies by 185.6% in the third quarter. Wealth Enhancement Advisory Services LLC now owns 8,810 shares of the biopharmaceutical company’s stock valued at $645,000 after purchasing an additional 5,725 shares in the last quarter. US Bancorp DE grew its holdings in shares of Intra-Cellular Therapies by 3.3% in the third quarter. US Bancorp DE now owns 7,951 shares of the biopharmaceutical company’s stock valued at $582,000 after purchasing an additional 251 shares in the last quarter. Harbor Capital Advisors Inc. grew its holdings in shares of Intra-Cellular Therapies by 144.6% in the third quarter. Harbor Capital Advisors Inc. now owns 34,974 shares of the biopharmaceutical company’s stock valued at $2,559,000 after purchasing an additional 20,676 shares in the last quarter. M&G PLC purchased a new position in shares of Intra-Cellular Therapies in the third quarter valued at $9,076,000. Finally, Principal Financial Group Inc. grew its holdings in shares of Intra-Cellular Therapies by 3.3% in the third quarter. Principal Financial Group Inc. now owns 597,713 shares of the biopharmaceutical company’s stock valued at $43,735,000 after purchasing an additional 18,865 shares in the last quarter. 92.33% of the stock is owned by hedge funds and other institutional investors.
Intra-Cellular Therapies Trading Down 0.0 %
NASDAQ ITCI opened at $131.24 on Wednesday. Intra-Cellular Therapies has a 12 month low of $63.30 and a 12 month high of $131.36. The stock has a market cap of $13.95 billion, a price-to-earnings ratio of -150.85 and a beta of 0.72. The company’s 50 day moving average is $119.20 and its two-hundred day moving average is $93.44.
Intra-Cellular Therapies (NASDAQ:ITCI – Get Free Report) last released its earnings results on Friday, February 21st. The biopharmaceutical company reported ($0.16) EPS for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.08). Intra-Cellular Therapies had a negative return on equity of 9.93% and a negative net margin of 14.07%. The firm had revenue of $199.22 million for the quarter, compared to the consensus estimate of $205.08 million. Sell-side analysts forecast that Intra-Cellular Therapies will post -0.64 EPS for the current year.
Intra-Cellular Therapies Company Profile
Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.
Recommended Stories
Receive News & Ratings for Intra-Cellular Therapies Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Intra-Cellular Therapies and related companies with MarketBeat.com’s FREE daily email newsletter.